Alfasigma launches diagnostic drug Lumeblue™ ahead of World Digestive Health 2022
May 27, 2022
Ahead of World Digestive Health 2022, Italian pharmaceutical group Alfasigma is proud to announce the launch of its new diagnostic drug Lumeblue™ (per-oral methylene blue). This latest innovation is part of the company’s commitment to raising awareness on colorectal cancer (CRC), still the second leading cause of cancer deaths worldwide, through a healthy lifestyle and regular screenings.
